# Enzastaurin Versus Lomustine in Glioblastoma

> **NCT00295815** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 397 (actual)

## Conditions studied

- Glioblastoma

## Interventions

- **DRUG:** enzastaurin
- **DRUG:** lomustine

## Key facts

- **NCT ID:** NCT00295815
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** 2007-08
- **Final completion:** 2014-05
- **Target enrollment:** 397 (ACTUAL)
- **Last updated:** 2019-09-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00295815

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00295815, "Enzastaurin Versus Lomustine in Glioblastoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00295815. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*